Explore comprehensive insights into antibodies, their functions, and latest research. Stay informed with expert analysis and updates in the field of immunology.
July 2026 was another active month for the antibody biotech sector, with deal activity ranging from multibillion-dollar acquisitions and antibody licensing agreements to ADC technology deals, AI-driven discovery partnerships, and major private financings. Immunology was a major focus, alongside growing investment in next-generation ADC payloads, multispecific antibodies, and AI-powered antibody discovery.
April 2026 activity saw consolidation in the ADC space, continued expansion of next-generation antibody formats (including DACs and trispecifics), and strong financing for platform-driven oncology innovation. Strategic M&A and high-value partnerships highlighted sustained interest in complex biologics and targeted delivery technologies.
March 2026 saw a surge in antibody dealmaking, focusing on T-cell engagers and autoimmune applications, alongside advancements in targeted protein degradation.
You can also contact us on the Scientist and Science Exchange marketplaces.